INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol MEDIORG
MSEI Symbol NOTLISTED
ISIN INE0PE401018
Name of Company Medicamen Organics Limited
Type of company SME
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-05-2026   15:00:00
End date and time of board meeting 29-05-2026   17:37:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 29-05-2026
Indicate Company website link for updated RPT policy of the Company https://www.medicamenorganics.com/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default


Financial Results — Other than Bank

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Revenue From Operations
Revenue from operations 459.63 2,164.80
Other income 1.50 7.24
Total Income 461.13 2,172.04
2 Expenses
(a) Cost of materials consumed 544.47 1,564.88
(b) Purchases of stock-in-trade 73.87 (39.03)
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 178.32 363.80
(e) Finance costs 37.26 70.58
(f) Depreciation and amortisation expense 47.53 88.73
(g) Other Expenses
1 Direct Expenses 117.30 272.78
2 Other Expenses 151.56 280.74
Total other expenses 268.86 553.52
Total expenses 1,150.31 2,602.48
3 Profit before exceptional and extraordinary items and tax (689.18) (430.44)
4 Exceptional items 0.00 0.00
5 Profit before extraordinary items and tax (689.18) (430.44)
6 Extraordinary items 0.00 0.00
7 Profit before tax (689.18) (430.44)
8 Tax Expense
Current tax (62.90) 0.00
Deferred tax (127.92) (125.90)
Total tax expenses (190.82) (125.90)
9 Net Profit Loss for the period from continuing operations (498.36) (304.54)
10 Profit (loss) from discontinuing operations before tax 0.00 0.00
11 Tax expense of discontinuing operations 0.00 0.00
12 Net profit (loss) from discontinuing operation after tax 0.00 0.00
13 Profit (loss) for period before minority interest (498.36) (304.54)
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period (498.36) (304.54)
17 Details of equity share capital
Paid-up equity share capital 1,216.59 1,216.59
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 0.00
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -4.24 -2.58
Diluted earnings (loss) per share from continuing and discontinued operations -4.21 -2.58
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio
23 Disclosure of notes on financial results Textual Information(1)


Text Block

Textual Information(1) 1. The standalone audited financial results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. 2. The Company has signed a Memorandum of Understanding (MOU) dated July 15, 2024 and a Share Sale Agreement dated October 08, 2024 with Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company), having its corporate office at Plot No. B1, Kigali City Market, Nyarugenge, Kigali-20093, Rwanda, East Africa. The Company has invested in a 51% stake in Depot Pharmacy Yego Ltd. While the transaction agreement was executed on October 08, 2024, the actual acquisition was completed on January 16, 2025, which is considered as the acquisition date. Further, the Company incorporated a subsidiary namely Grande Etoile Pharmaceuticals Limited on December 27, 2024, in which the Company holds 50.92% shareholding. 3. The Statutory Auditors of the Company have audited the above results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 4. There were no investor complaints pending at the beginning or at the end of the half-year ended March 31, 2026. 5. The financial results are also available on the websites of the Company at www.medicamenorganics.com and NSE at www.nseindia.com. 6. The above standalone audited financial results for the half-year and year ended March 31, 2026 were reviewed and recommended by the Audit Committee and subsequently approved and taken on record by the Board of Directors at their respective meetings held on May 29, 2026. The results have been audited by the Statutory Auditors of the Company. 7. The Company has received intimation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006. Necessary disclosures relating to outstanding dues as at the year end have been made. The Company has also provided for interest on outstanding dues payable to MSME suppliers as on March 31, 2026. 8. The results for the half-year and year ended March 31, 2026 have been audited by the Statutory Auditors in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015. 9. These financial results have been prepared in accordance with the recognition and measurement principles laid down under Accounting Standards (AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other generally accepted accounting principles in India. 10. Earnings Per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 on Earnings Per Share. EPS for the half-years ended March 31, 2026, September 30, 2025 and March 31, 2025 have not been annualised. The weighted average number of equity shares outstanding during the respective periods has been considered for computing Basic and Diluted EPS. 11. Comparative figures for the half-year and year ended March 31, 2026 have been audited by the Statutory Auditors of the Company. 12. The figures for the half-year ended March 31, 2026 represent the balancing figures between the audited figures for the full financial year ended March 31, 2026 and the unaudited figures for the half-year ended September 30, 2025. 13. The Company issued 31,00,000 equity shares of face value 10 each at a premium of 24 per share through an Initial Public Offer (IPO) and was listed on the NSE Emerge Platform on June 28, 2024. . Contingent Liabilities and Pending Litigations 14A. Contingent Liabilities ( in Lakhs) Particulars Next Date of Hearing As at 31.03.2026 As at 31.03.2025 Case against the Company filed by Prakash Parcel Services Ltd. 20.08.2026 2.34 2.34 Case against the Company filed by Multani Pharmaceuticals 29.05.2026 7.18 Nil Margin Money (FDR) for Bank Guarantee on behalf of third party (Margin FDR of 56,200) - 5.62 6.42 14B. Statutory Dues under Dispute Statute Nature of Dues Amount ( in Lakhs) Financial Year Description Forum Income Tax Department Income Tax 13.27 AY 2017-18 Assessment Year Commissioner of Income Tax (Appeals) GST Difference in Output Tax Liability & ITC Claimed 17.74 FY 2022-23 Reply to be filed Deputy Commissioner (Assessment)-2, Haridwar 14C. Pending Litigations Party Name Nature Amount ( in Lakhs) Next Hearing Description Forum Europa Biocare Pvt. Ltd. Civil Case 7.23 29.07.2026 Recovery suit filed by Company Rohini Court Wafture Healthcare Pvt. Ltd. Civil Case 5.70 19.09.2026 Recovery suit filed by Company Rohini Court Paseca Health Care Civil Case 5.53 29.07.2026 Recovery suit filed by Company Rohini Court Ujjwal Overseas Civil Case 17.17 29.07.2026 Recovery suit filed by Company Rohini Court Mex Life Care Ltd. Civil Case (NI Act) 13.72 01.08.2026 Recovery suit filed by Company Rohini Court 15. During FY 2024-25, the Company undertook an IPO of 31,00,000 equity shares of face value 10 each at an issue price of 34 per share (including premium of 24 per share), aggregating 1,054.00 lakhs. The shares were allotted on June 26, 2024 and listed on NSE Emerge on June 28, 2024. 16. The Company has written off 33.09 lakhs being GST refund receivable which is no longer recoverable from the GST Department. 17. The GST Department, Uttarakhand is conducting scrutiny of the Company's GST returns for FY 2024-25. During the year, the Company voluntarily paid 50.00 lakhs through Form GST DRC-03. Management believes that no further material liability is likely to arise and accordingly no additional provision has been recognised. 18. During FY 2025-26, the Company issued 4,65,910 warrants convertible into equivalent number of equity shares of face value 10 each at an issue price of 64.39 per warrant, in accordance with SEBI ICDR Regulations, 2018. 19. Pursuant to Special Resolution dated January 24, 2026, 4,65,910 warrants were converted into fully paid-up equity shares and allotted to Mr. Bal Kishan Gupta at an issue price of 64.39 per share. 20. Sundry creditors include advance received of 40.21 lakhs from Escorts Pharmaceuticals Rwanda Limited (EPRL) in March 2025. No supplies were executed against this advance up to March 31, 2026 due to geopolitical tensions and logistical disruptions in the East African region, including Rwanda-DRC border instability. The matter is under continuous review and the Company is coordinating with the customer and logistics partners. 21. Balances of certain debtors and creditors are subject to confirmation and reconciliation. 22. Based on management assessment, the recoverable value of assets exceeds their carrying amount and therefore no impairment provision is required. 23. Previous year/period figures have been regrouped and reclassified wherever necessary to conform to current year classifications. 24. Since the Company operates in a single business segment, the disclosure requirements under AS-17 Segment Reporting are not applicable.


Remarks

20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect

Amount in (Lakhs)

A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax (430.44)
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 0.00
Adjustments for depreciation and amortisation expense 61.96
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for share-based payments 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments to profit (loss) 61.96
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories (280.56)
Adjustments for decrease (increase) in trade receivables 677.93
Adjustments for decrease (increase) in other current assets 21.71
Adjustments for increase (decrease) in trade payables (629.17)
Adjustments for increase (decrease) in other current liabilities 95.32
Adjustments for provisions (109.71)
Total adjustments for working capital (224.48)
Total adjustments for reconcile profit (loss) (162.52)
Net cash flows from (used in) operations (592.96)
Dividends received 0.00
Interest paid (70.58)
Interest received (2.23)
Income taxes paid (refund) 12.47
Other inflows (outflows) of cash 121.97
Net cash flows from (used in) operating activities before extraordinary items (415.11)
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) operating activities (415.11)
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.09
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property plant and equipment 0.00
Purchase of property plant and equipment 164.66
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 2.23
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Proceeds from government grants 0.00
Net cash flows from (used in) investing activities before extraordinary items (162.52)
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) investing activities (162.52)
Cash flows from used in financing activities
Proceeds from issuing shares 46.59
Proceeds from issuing other equity instruments (75.00)
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 155.95
Repayments of borrowings 0.00
Dividends paid 0.00
Interest paid 70.58
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 253.41
Net cash flows from (used in) financing activities before extraordinary items 310.37
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) financing activities 310.37
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (267.26)
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (267.26)
Cash and cash equivalents cash flow statement at beginning of period 326.91
Cash and cash equivalents cash flow statement at end of period 59.65


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 1,216.59
Reserves and surplus 1,663.97
Money received against share warrants
Total shareholders' funds 2,880.56
2 Share application money pending allotment 0.00
3 Deferred government grants
4 Minority interest
5 Non-current liabilities
Long-term borrowings 104.50
Deferred tax liabilities (net)
Foreign currency monetary item translation difference liability account
Other long-term liabilities
Total of Other long-term liabilities
Long-term provisions 24.77
Total non-current liabilities 129.27
6 Current liabilities
Short-term borrowings 1,264.41
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 124.27
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 416.32
Total Trade payable 540.59
Other current liabilities
1 other current liabilities 228.13
Total of Other long-term liabilities 228.13
Short-term provisions 5.99
Total current liabilities 2,039.12
Total equity and liabilities 5,048.95
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 1,283.20
Producing properties
Intangible assets 44.94
Preproducing properties
Property, Plant and Equipment capital work-in-progress 9.21
Intangible assets under development or work-in-progress
Total Property, Plant and Equipment and Intangible assets 1,337.35
ii Non-current investments 27.09
v Deferred tax assets (net) 9.91
vi Foreign currency monetary item translation difference asset account
vii Long-term loans and advances 0.00
Other non-current assets
1 other non-current assets 119.48
Total of Other non-current assets 119.48
Total non-current assets 1,493.83
Current assets
Current investments 0.00
Inventories 1,029.50
Trade receivables 1,797.28
Cash and cash equivalents 59.65
Bank balance other than cash and cash equivalents 0.00
Short-term loans and advances 668.69
Other current assets
Total of Other current assets
Total current assets 3,555.12
Total assets 5,048.95
Disclosure of notes on assets and liabilities Textual Information(1)


Text Block

Textual Information(1) 1. The standalone audited financial results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. 2. The Company has signed a Memorandum of Understanding (MOU) dated July 15, 2024 and a Share Sale Agreement dated October 08, 2024 with Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company), having its corporate office at Plot No. B1, Kigali City Market, Nyarugenge, Kigali-20093, Rwanda, East Africa. The Company has invested in a 51% stake in Depot Pharmacy Yego Ltd. While the transaction agreement was executed on October 08, 2024, the actual acquisition was completed on January 16, 2025, which is considered as the acquisition date. Further, the Company incorporated a subsidiary namely Grande Etoile Pharmaceuticals Limited on December 27, 2024, in which the Company holds 50.92% shareholding. 3. The Statutory Auditors of the Company have audited the above results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 N C RAJ & ASSOCIATES Yes 28-02-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 26-06-2024
Amount Raised 1,054.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders Yes
If Yes, Date of shareholder Approval 27-01-2026
Explanation for the Deviation / Variation Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus
Comments of the Audit Committee after review Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs. 300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). However, the Company no longer requires these funds for such a purpose. On February 26, 2026, a Special resolution was passed to consider and approve a variation in the objects of the issue relating to the initial public offering (IPO) for which the amount was raised through a prospectus.
Comments of the auditors, if any No comments from the auditor
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Funding of expenses proposed to be incurred towards Product registration in the international markets; Yes 300.00 162.44 137.56 162.44 1. The Company came up with the public issue of 31,00,000 equity shares of Face value of Rs.10/- each (equity shares) with the price band of Rs.32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each (equity shares) for cash at a price of Rs. 34/- per equity share (including a share premium of Rs. 24 per equity share) aggregating to Rs. 10,54,00,000 on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. 2. Cumulative fund utilized as on March 31st 2026 is Rs. 1054,00,000 3. Funding of expenses proposed to be incurred towards Product registration in the international markets ot Rs.300 Lakhs, out of the amount, Rs.162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the Unutilized Amount), however, the Company no longer requires these funds for such purpose, on February 26, 2026, Special resolution passed to consider and approve variation in the objects of the issue relating to initial public offering (ipo) for which amount was raised through prospectus. The unutilized IPO proceeds of Rs. 162.44 (In lakhs) i.e. 15.41% of IPO proceeds, is intended to be utilized towards the following purposes. S.No. 1 Object of the Issue as per DRHP - expenses proposed to be incurred towards Product registration in the international markets Utilisation Planned as per prospectus - 300 Amount actually Utilised by the company - 137.56 Balance available for Utilisation - 162.44 Revised Object as per Special resolution - To meet out the working capital requirements of our company Amount to be funded from the IPO Proceeds - 162.44
2 Plant updation and increase in production capacity No 225.00 0.00 225.00 0.00
3 Funding working capital requirements of our Company No 400.00 0.00 562.44 0.00
4 General corporate purpose No 39.00 0.00 39.00 0.00
5 Issue Related Expenses No 90.00 0.00 90.00 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 13-03-2025
Amount Raised 299.99
Report filed for Quarter ended 31-03-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation false
Comments of the Audit Committee after review false
Comments of the auditors, if any false
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Working capital requirements and General corporate purpose No 299.99 0.00 299.99 0.00 As on March 31, 2026, funds received against the warrants subscription money on 4,65,910 warrants amounted to Rs. 2,99,99,945,. The Company has spent total funds towards the objects disclosed in the offer document/Postal Ballot Notice. 1. During the financial year ended March 31, 2026, the Company came up with the preferential issue of 4,65,910 warrants convertible into equivalent number of fully paid-up equity shares of face value of ? 10/- (Rupee Ten Only) each (Equity Shares) at the option of Allottees, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of Rs. 64.39/-. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. 2. Cumulative fund utilized as on March 31, 2026 is Rs. 299.99


Signatory Details

Name of signatory Bal Kishan Gupta
Designation of person Managing Director
Place New Delhi
Date 29-05-2026


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Medicamen Organics Limited Grande Etoile Pharmaceuticals Limited The company has formed subsidiary with 50.96% shareholding Investment No Remarks 0.00 25.46 25.46
2 Medicamen Organics Limited Grande Etoile Pharmaceuticals Limited The company has formed subsidiary with 50.96% shareholding Loan No Remarks 50.46 0.00 50.46
3 Medicamen Organics Limited Grande Etoile Pharmaceuticals Limited The company has formed subsidiary with 50.96% shareholding Any other transaction Reimbursement of expenses No Remarks 0.00 0.31 0.31
4 Medicamen Organics Limited Depot Yego Pharmacy Limited The compoany has acquired 51% shareholding in the company Investment No Remarks 0.00 1.63 1.63
5 Medicamen Organics Limited Redline Healthcare Private Limited Associate Concern Loan No Remarks 8.91 10.69 2.80
6 Medicamen Organics Limited Redline Healthcare Private Limited Director is a parter Loan No Remarks 0.00 3.80 3.80
7 Medicamen Organics Limited Bal Kishan Gupta Director Remuneration No Remarks 17.52 1.62 5.65
8 Medicamen Organics Limited Bal Kishan Gupta Director Loan No Remarks 146.85 712.18 565.33
9 Medicamen Organics Limited Ritu Gupta Director's Spouse Remuneration No Remarks 7.39 0.80 2.80
10 Medicamen Organics Limited Ashutosh Gupta Director Remuneration No Remarks 27.78 1.84 5.24
11 Medicamen Organics Limited Ashutosh Gupta Director Loan No Remarks 1.12 0.00 1.12
12 Medicamen Organics Limited Shivani Chopra Shareholder Remuneration No Remarks 18.41 1.21 2.07
13 Medicamen Organics Limited BKG and Sons HUF Director's HUF Loan No Remarks 0.00 0.00 0.00
14 Medicamen Organics Limited Brijesh Kumar Chaubey Director Remuneration No Remarks 16.04 1.36 1.62
15 Medicamen Organics Limited Jasbal Pharma LLP LLP in which director is Partner Sale of goods or services No Remarks 5.71 0.75 3.46
16 Medicamen Organics Limited Loire Cosmetics Limited Grande Etoile Pharmaceuticals Limited Subsidiary Investment No Remarks 2.54 0.00 2.54
17 Medicamen Organics Limited Sneh Gaur Non Executive Director Any other transaction Sitting fees No Remarks 0.50 2.25 1.70
18 Medicamen Organics Limited Rajinder Kumar Gupta Independent Director Any other transaction Sitting fees No Remarks 0.70 0.45 0.78
19 Medicamen Organics Limited Sachin Gupta Independent Director Any other transaction Sitting fees No Remarks 0.75 0.45 0.83
20 Medicamen Organics Limited Rakesh Kumar Independent Director Any other transaction Sitting fees No Remarks 0.30 0.45 0.42
21 Medicamen Organics Limited Lalit Gupta Chief Financial Officer Any other transaction Salary No Remarks 12.40 0.65 1.25
22 Medicamen Organics Limited Varsha Bansal Company Secretary Any other transaction Salary including PF No Remarks 1.80 0.13 0.13
Total value of transaction during the reporting period 319.18